SUPERNUS PHARMACEUTICALS, INC. Increase (Decrease) in Accrued Liabilities
SUPERNUS PHARMACEUTICALS, INC. (SUPN) reported Increase (Decrease) in Accrued Liabilities of $10.43 million for the 12-month period ending 2018-12-31, per its 10-K filed 2019-03-01.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2019-03-01
- SUPERNUS PHARMACEUTICALS, INC. increase (decrease) in accrued liabilities for the quarter ending 2018-12-31 was $4.47M, a 3652.94% increase year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. increase (decrease) in accrued liabilities for the quarter ending 2018-09-30 was $3.00M, a 25.91% decline year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. increase (decrease) in accrued liabilities for the quarter ending 2018-06-30 was $4.10M, a 603.78% increase year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. increase (decrease) in accrued liabilities for the quarter ending 2018-03-31 was -$1.13M.
- SUPERNUS PHARMACEUTICALS, INC. increase (decrease) in accrued liabilities for fiscal 2018 was $10.43M, a 261.22% increase from fiscal 2017.
- SUPERNUS PHARMACEUTICALS, INC. increase (decrease) in accrued liabilities for fiscal 2017 was $2.89M, a 61.69% decline from fiscal 2016.
- SUPERNUS PHARMACEUTICALS, INC. increase (decrease) in accrued liabilities for fiscal 2016 was $7.54M, a 1386.98% increase from fiscal 2015.
- SUPERNUS PHARMACEUTICALS, INC. increase (decrease) in accrued liabilities for fiscal 2015 was $507.00K, a 75.04% decline from fiscal 2014.
| Period end | Increase (Decrease) in Accrued Liabilities 3 month | Increase (Decrease) in Accrued Liabilities 3 month as first filed | Increase (Decrease) in Accrued Liabilities 6 month | Increase (Decrease) in Accrued Liabilities 6 month as first filed | Increase (Decrease) in Accrued Liabilities 9 month | Increase (Decrease) in Accrued Liabilities 9 month as first filed | Increase (Decrease) in Accrued Liabilities 12 month | Increase (Decrease) in Accrued Liabilities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2018-12-31 | $4.47M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | $7.47M derived: sum of 2 quarters · filed 2019-03-01 | $11.56M derived: sum of 3 quarters · filed 2019-03-01 | $10.43M 10-K · filed 2019-03-01 | ||||
| 2018-09-30 | $3.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-09 | $7.10M derived: sum of 2 quarters · filed 2018-11-09 | $5.97M 10-Q · filed 2018-11-09 | $6.08M derived: sum of 4 quarters · filed 2019-03-01 | ||||
| 2018-06-30 | $4.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | $2.96M 10-Q · filed 2018-08-09 | $3.08M derived: sum of 3 quarters · filed 2019-03-01 | $7.13M derived: sum of 4 quarters · filed 2019-03-01 | ||||
| 2018-03-31 | -$1.13M 10-Q · filed 2018-05-10 | -$1.01M derived: sum of 2 quarters · filed 2019-03-01 | $3.04M derived: sum of 3 quarters · filed 2019-03-01 | $3.62M derived: sum of 4 quarters · filed 2019-03-01 | ||||
| 2017-12-31 | $119.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | $4.17M derived: sum of 2 quarters · filed 2019-03-01 | $4.75M derived: sum of 3 quarters · filed 2019-03-01 | $2.89M 10-K · filed 2019-03-01 | ||||
| 2017-09-30 | $4.05M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-09 | $4.63M derived: sum of 2 quarters · filed 2018-11-09 | $2.77M 10-Q · filed 2018-11-09 | $7.80M derived: sum of 4 quarters · filed 2019-03-01 | ||||
| 2017-06-30 | $582.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | -$1.28M 10-Q · filed 2018-08-09 | $3.75M derived: sum of 3 quarters · filed 2019-03-01 | $8.84M derived: sum of 4 quarters · filed 2019-03-01 | ||||
| 2017-03-31 | -$1.86M 10-Q · filed 2018-05-10 | $3.17M derived: sum of 2 quarters · filed 2019-03-01 | $8.26M derived: sum of 3 quarters · filed 2019-03-01 | $11.69M derived: sum of 4 quarters · filed 2019-03-01 | ||||
| 2016-12-31 | $5.04M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | $10.12M derived: sum of 2 quarters · filed 2019-03-01 | $13.56M derived: sum of 3 quarters · filed 2019-03-01 | $7.54M 10-K · filed 2019-03-01 | $7.55M 10-K · filed 2017-03-16 | |||
| 2016-09-30 | $5.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $8.52M derived: sum of 2 quarters · filed 2017-11-09 | $2.50M 10-Q · filed 2017-11-09 | $3.31M 10-Q · filed 2017-01-20 | $3.47M derived: sum of 4 quarters · filed 2018-03-01 | |||
| 2016-06-30 | $3.43M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | -$2.58M 10-Q · filed 2017-08-03 | -$2.25M 10-Q · filed 2016-08-05 | -$1.62M derived: sum of 3 quarters · filed 2018-03-01 | $1.26M derived: sum of 4 quarters · filed 2018-03-01 | |||
| 2016-03-31 | -$6.02M 10-Q · filed 2017-05-09 | -$6.00M 10-Q · filed 2016-05-10 | -$5.05M derived: sum of 2 quarters · filed 2018-03-01 | -$2.17M derived: sum of 3 quarters · filed 2018-03-01 | -$3.63M derived: sum of 4 quarters · filed 2018-03-01 | |||
| 2015-12-31 | $966.00K derived: 10-K 12 month − 10-Q/A 9 month · filed 2018-03-01 | $3.85M derived: sum of 2 quarters · filed 2018-03-01 | $2.39M derived: sum of 3 quarters · filed 2018-03-01 | $507.00K 10-K · filed 2018-03-01 | -$1.60M 10-K · filed 2016-03-09 | |||
| 2015-09-30 | $2.88M derived: 10-Q/A 9 month − 10-Q/A 6 month · filed 2017-01-20 | $1.42M derived: sum of 2 quarters · filed 2017-01-23 | -$459.00K 10-Q/A · filed 2017-01-20 | -$2.54M 10-Q · filed 2015-11-09 | $2.17M derived: sum of 4 quarters · filed 2017-03-16 | |||
| 2015-06-30 | -$1.46M derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2017-01-23 | -$3.34M 10-Q/A · filed 2017-01-23 | $6.27M 10-Q · filed 2015-08-07 | -$712.00K derived: sum of 3 quarters · filed 2017-03-16 | -$3.37M derived: sum of 4 quarters · filed 2017-03-16 | |||
| 2015-03-31 | -$1.88M 10-Q/A · filed 2017-01-20 | $366.00K 10-Q · filed 2015-05-06 | $746.00K derived: sum of 2 quarters · filed 2017-03-16 | -$1.91M derived: sum of 3 quarters · filed 2017-03-16 | $2.83M derived: sum of 4 quarters · filed 2017-03-16 | |||
| 2014-12-31 | $2.63M derived: 10-K 12 month − 10-Q/A 9 month · filed 2017-03-16 | -$28.00K derived: sum of 2 quarters · filed 2017-03-16 | $4.71M derived: sum of 3 quarters · filed 2017-03-16 | $2.03M 10-K · filed 2017-03-16 | $10.31M 10-K · filed 2015-03-12 | |||
| 2014-09-30 | -$2.66M derived: 10-Q/A 9 month − 10-Q 6 month · filed 2017-01-20 | $2.08M derived: sum of 2 quarters · filed 2017-01-20 | -$598.00K 10-Q/A · filed 2017-01-20 | $6.45M 10-Q · filed 2015-11-09 | ||||
| 2014-06-30 | $4.74M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-07 | $2.06M 10-Q · filed 2015-08-07 | ||||||
| 2014-03-31 | -$2.68M 10-Q · filed 2015-05-06 | |||||||
| 2013-12-31 | $7.16M 10-K/A · filed 2017-01-20 | $8.16M 10-K · filed 2015-03-12 | ||||||
| 2012-12-31 | -$1.42M 10-K · filed 2015-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |